|
KMID : 1191520180230020011
|
|
Journal of Korean Traditional Oncology
2018 Volume.23 No. 2 p.11 ~ p.25
|
|
|
A Case of End-stage non-small cell Lung Cancer Patient with Brain Metastasis Treated with Pembrolizumab with Integrative Medicine Therapy
|
|
Seo Han-Gil
Jin Yong-Jae
Song Mi-Hwa
Kim In-Tae
Park Ji-Hye
Jung Jun-Suk
Cho Sung-Klyoo
Shin Kwang-Soon
|
|
|
Abstract
|
|
|
Objective: The purpose of this study is to report the case of a patient with non-small cell lung cancer (NSCLC) with Programmed cell death protein 1 (PD-1) mutation treated by Integrative Medicine Therapy (IMT).
Methods: A patient with metastatic NSCLC received pembrolizumab 200mg intravenously for every 3 weeks from July 2017. Repeat cycle every 3 weeks since July 2017. The patient has been treated with Integrative Medicine Therapy (IMT) since December 2016. The tumor size was measured by computed tomography (CT) and magnetic resonance imaging(MRI). Adverse events were evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.
Results: After combined treatment, the extent of proximal portion of primary tumor in the left lower lobe was decreased and disease status was stable radiologically. No evidence of newly developed metastatic lesions in the brain since May 2017. The patient did not experience any adverse event according to NCI-CTCAE ver. 5.0.
Conclusion: This case study suggests that Integrative Medicine Therapy (IMT) may contribute to tumor response, in conjunction with Pembrolizumab on the treatment of patients with NSCLC.
|
|
|
KEYWORD
|
|
|
Non-Small-Cell Lung cancer, Integrative Medicine, Metastasis, Korean Herbal Medicine, Pembrolizumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|